The combination of histone deacetylase inhibitors and radiotherapy: a promising novel approach for cancer treatment
- 20 August 2020
- journal article
- review article
- Published by Taylor & Francis in Future Oncology
- Vol. 16 (30) , 2457-2469
Abstract
HDAC inhibitors (HDACi) play an essential role in various cellular processes, such as differentiation and transcriptional regulation of key genes and cytostatic factors, cell cycle arrest and apopt...Keywords
This publication has 80 references indexed in Scilit:
- Histone deacetylase inhibitors as radiosensitisers: effects on DNA damage signalling and repairBritish Journal of Cancer, 2013
- Structure of HDAC3 bound to co-repressor and inositol tetraphosphateNature, 2012
- Grand rounds at the National Institutes of Health: HDAC inhibitors as radiation modifiers, from bench to clinicJournal of Cellular and Molecular Medicine, 2011
- Histone Deacetylase Inhibitors: Emerging Mechanisms of ResistanceMolecular Pharmaceutics, 2011
- Therapeutic Strategies to Enhance the Anticancer Efficacy of Histone Deacetylase InhibitorsBioMed Research International, 2011
- HDAC Inhibitor, Valproic Acid, Induces p53-Dependent Radiosensitization of Colon Cancer CellsCancer Biotherapy and Radiopharmaceuticals, 2009
- Vorinostat enhances the radiosensitivity of a breast cancer brain metastatic cell line grown in vitro and as intracranial xenograftsMolecular Cancer Therapeutics, 2009
- Will histone deacetylase inhibitors require combination with other agents to fulfil their therapeutic potential?British Journal of Cancer, 2008
- Anticancer activities of histone deacetylase inhibitorsNature Reviews Drug Discovery, 2006
- Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancerNature Reviews Cancer, 2006